Compare MCO & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCO | MRNA |
|---|---|---|
| Founded | 1900 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4B | 91.2B |
| IPO Year | 1998 | 2018 |
| Metric | MCO | MRNA |
|---|---|---|
| Price | $470.14 | $196.25 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 24 | 23 |
| Target Price | ★ $553.67 | $164.53 |
| AVG Volume (30 Days) | 765.2K | ★ 11.3M |
| Earning Date | 10-21-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | 21.40 | ★ 21.77 |
| EPS | ★ 12.98 | N/A |
| Revenue | $4,204,100,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $6.50 | $24.09 |
| Revenue Next Year | $6.70 | $11.33 |
| P/E Ratio | $36.35 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $402.28 | $23.55 |
| 52 Week High | $546.88 | $280.80 |
| Indicator | MCO | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 41.43 |
| Support Level | $460.33 | $181.02 |
| Resistance Level | $476.73 | $254.48 |
| Average True Range (ATR) | 12.25 | 18.33 |
| MACD | -5.50 | -7.45 |
| Stochastic Oscillator | 3.58 | 5.92 |
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and often (depending on bond issuance levels) a majority of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.